Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.44 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118098 | 0.87 | NSD2 (0.63) | NSD2POLBCYP2A6SIGMAR1TMEM97 | |
| SCHEMBL5317572 | 0.84 | NSD2 (0.60) | NSD2POLBCYP2A6SIGMAR1TMEM97 | |
| SCHEMBL19049393 | 0.83 | NSD2 (0.58) | NSD2POLBALDH1A1SMN1; SMN2CYP2A6 | |
| SCHEMBL14540450 | 0.81 | NSD2 (0.57) | NSD2POLBCYP2A6SIGMAR1TMEM97 | |
| SCHEMBL19002498 | 0.80 | NSD2 (0.56) | NSD2POLBALDH1A1SMN1; SMN2CYP2A6 | |
| SCHEMBL10194674 | 0.80 | NSD2 (0.56) | NSD2POLBCYP2A6SIGMAR1TMEM97 | |
| SCHEMBL24827589 | 0.79 | NSD2 (0.55) | NSD2POLBALDH1A1SMN1; SMN2CYP2A6 | |
| SCHEMBL19002504 | 0.79 | NSD2 (0.55) | NSD2POLBALDH1A1SMN1; SMN2CYP2A6 | |
| SCHEMBL6361556 | 0.79 | NSD2 (0.51) | NSD2POLBCYP2A6SIGMAR1TMEM97 | |
| SCHEMBL6163419 | 0.79 | NSD2 (0.58) | NSD2POLBALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10674727-B2 | Substituted oxadiazoles for combating phytopathogenic fungi | BASF SE (DE) | 2020-06-09 | — | — | US | disclosed |
| US-20180368409-A1 | SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2018-12-27 | — | — | US | disclosed |
| EP-3376868-A1 | SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2018-09-26 | — | — | EP | disclosed |
| US-7816357-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10674727-B2 | Substituted oxadiazoles for combating phytopathogenic fungi | CYP51A1, FOXO3, NOXO1 | NSD2 2825/4885POLB 3297/4885ALDH1A1 666/4885 |
| US-20180368409-A1 | SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | CYP51A1, FOXO3, NOXO1 | NSD2 2825/4885POLB 3297/4885ALDH1A1 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.